TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells

Molecular Cancer Research

Volumn 11, Issue 10, 2013, Pages 1179-1192

  Fam, Hok Khim ^a,b   Walton, Cheryl ^a,b   Mitra, Sheetal A ^b   Chowdhury, Miraj ^a,b   Osborne, Nichola ^a,b   Choi, Kunho ^a,b   Sun, Guobin ^a,c   Wong, Patrick C W ^a,f   O'Sullivan, Maureen J ^b,d,f   Turashvili, Gulisa ^e   Aparicio, Samuel ^e   Triche, Timothy J ^b   Bond, Mason ^a,c   Pallen, Catherine J ^a,c   Boerkoel, Cornelius F ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^d Departments of Pathology and Laboratory Medicine University of British Columbia ^*  (United States)

^e OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^f TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHODIESTERASE; TYROSYL DNA PHOSPHODIESTERASE 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CAMPTOTHECIN; GLUCOSE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; TDP1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CHILDHOOD CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; EVENT FREE SURVIVAL; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SURVIVAL RATE; TDP1 GENE; TISSUE MICROARRAY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHILD; GENE INACTIVATION; GENETICS; METABOLISM; MUTATION; MYOBLAST; PATHOLOGY; PHYSIOLOGY; SERUM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; CAMPTOTHECIN; CELL LINE, TUMOR; CHILD; DNA REPAIR; GENE EXPRESSION PROFILING; GENE KNOCKOUT TECHNIQUES; GLUCOSE; HUMANS; MUTATION; MYOBLASTS, SKELETAL; PHOSPHORIC DIESTER HYDROLASES; POLY(ADP-RIBOSE) POLYMERASES; RHABDOMYOSARCOMA; SERUM; TISSUE ARRAY ANALYSIS;

EID: 84886445958     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0575     Document Type: Article

References (51)

1. Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol 2009;46:52-63.
2. Hingorani P, Kolb EA. Past, present, and future of therapies in pediatric sarcomas. Future Oncol 2010;6:605-18.
3. Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther 2010;87:543-52.
4. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol 1999;9: M57-60.
5. Pinilla-Ibarz J, Quintas-Cardama A. New agents in the treatment of chronic myelogenous leukemia. J Natl Compr Canc Netw 2009;7: 1028-37.
6. Bartek J, Lukas J, Bartkova J. DNA damage response as an anticancer barrier: damage threshold and the concept of "conditional haploinsufficiency". Cell Cycle 2007;6:2344-7.
7. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Mergui-Roelvink M, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361: 123-34.
8. Dagher R, Helman L. Rhabdomyosarcoma: an overview. Oncologist 1999;4:34-44.
9. Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate- risk rhabdomyosarcoma: Children,s Oncology Group Study D9803. J Clin Oncol 2009;27:5182-8.
10. Ellison LF, Pogany L, Mery LS. Childhood and adolescent cancer survival: a period analysis of data from the Canadian Cancer Registry. Eur J Cancer 2007;43:1967-75.
11. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994;94:445-8.
12. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;3:113-7.
13. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994;54:2869-72.
14. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001;11:289-97.
15. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1190-7.
16. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, et al. PARP-1 inhibition as a targeted strategy to treat Ewing,s sarcoma. Cancer Res 2012;72:1608-13.
17. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.
18. Mascarenhas L, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Paidas CN, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children,s Oncology Group. J Clin Oncol 2010;28:4658-63.
19. Liu C, Zhou S, Begum S, Sidransky D, Westra WH, Brock M, et al. Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer 2007;55:303-11.
20. Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children,s Oncology Group study. J Clin Oncol 2004;22:1398-403.
21. Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children,s Oncology Group. J Clin Oncol 2007;25: 362-9.
22. Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W. Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch 2011;458:55-64.
23. Goncalves A, Finetti P, Sabatier R, Gilabert M, Adelaide J, Borg JP, et al. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat 2011;127: 273-81.
24. Nosho K, Yamamoto H, Mikami M, Taniguchi H, Takahashi T, Adachi Y, et al. Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur J Cancer 2006;42: 2374-81.
25. Hirano R, Interthal H, Huang C, Nakamura T, Deguchi K, Choi K, et al. Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation? EMBO J 2007;26:4732-43.
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
27. Murai J, Huang SY, Das BB, Dexheimer TS, Takeda S, Pommier Y, et al. Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells. J Biol Chem 2012;287:12848-57.
28. Jensen PW, Falconi M, Kristoffersen EL, Simonsen AT, Cifuentes JB, Marcussen LB, et al. Real-time detection of TDP1 activity using a fluorophore-quencher coupled DNA-biosensor. Biosens Bioelectron 2013;48C:230-7.
29. Boerkoel CF, Takashima H, Garcia CA, Olney RK, Johnson J, Berry K, et al. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol 2002;51: 190-201.
30. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44.
31. Aly A, Ganesan S. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol 2011;3:66-74.
32. Siggens L, Figg N, Bennett M, Foo R. Nutrient deprivation regulates DNA damage repair in cardiomyocytes via loss of the base-excision repair enzyme OGG1. FASEB J 2012;26:2117-24.
33. Mathews MT, Berk BC. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler Thromb Vasc Biol 2008;28:711-7.
34. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin- Montalvo A, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 2012;4: 124ra27.
35. El-Khamisy SF, Saifi GM, Weinfeld M, Johansson F, Helleday T, Lupski JR, et al. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 2005;434:108-13.
36. Katyal S, el-Khamisy SF, Russell HR, Li Y, Ju L, Caldecott KW, et al. TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo. EMBO J 2007;26:4720-31.
37. Messina A, Puccinelli E, Gervasi PG, Longo V. Expression and inducibility of CYP1A1, 1A2, 1B1 by beta-naphthoflavone and CYP2B22, CYP3As by rifampicin in heart regions and coronary arteries of pig. Res Vet Sci 2013;94:77-83.
38. Chiarugi A. A snapshot of chemoresistance to PARP inhibitors. Trends Pharmacol Sci 2012;33:42-8.
39. Plo I, Liao ZY, Barceló JM, Kohlhagen G, Caldecott KW, Weinfeld M, et al. Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst) 2003;2:1087-100.
40. Schultz N, Lopez E, Saleh-Gohari N, Helleday T. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 2003;31:4959-64.
41. Ray Chaudhuri A, Hashimoto Y, Herrador R, Neelsen KJ, Fachinetti D, Bermejo R, et al. Topoisomerase I poisoning results in PARP-mediated replication fork reversal. Nat Struct Mol Biol 2012;19:417-23.
42. Kim MY, Mauro S, G évry N, Lis JT, Kraus WL. NADβ-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 2004;119:803-14.
43. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010;17:688-95.
44. Bunting SF, Callén E, Wong N, Chen HT, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010;141:243-54.
45. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, et al. Analysis of tumor metabolismreveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab 2012;15:827-37.
46. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
47. Graham NA, Tahmasian M, Kohli B, Komisopoulou E, Zhu M, Vivanco I, et al. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol Syst Biol 2012;8:589.
48. Das BB, Dexheimer TS, Maddali K, Pommier Y. Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondria. Proc Natl Acad Sci U S A 2010;107:19790-5.
49. Luo X, Kraus WL. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 2012;26:417-32.
50. Fam HK, Chowdhury MK, Walton C, Choi K, Boerkoel CF, Hendson G. Expression profile and mitochondrial colocalization of Tdp1 in peripheral human tissues. J Mol Histol 2013;44:481-94.
51. Rodriguez-Vargas JM, Ruiz-Magaña MJ, Ruiz-Ruiz C, Majuelos-Melguizo J, Peralta-Leal A, Rodríguez MI, et al. ROS-induced DNA damage and PARP-1 are required for optimal induction of starvationinduced autophagy. Cell Res 2012;22:1181-98.